58.9 F
San Diego
Monday, Mar 18, 2024
-Advertisement-

Stemgent to Sell Pfizer Research Products

Pfizer Inc. said April 15 that it will begin selling reagents for use in stem cell research through Stemgent Inc., a biotech with operations in Boston and San Diego.

Under terms of the agreement, Stemgent will sell fully licensed compounds as off-the-shelf products for use in stem cell research.

Financial terms of the collaboration were not revealed.

Pfizer said the collaboration could serve to benefit researchers testing a range of stem cell and cell-based applications, including neuroscience, cancer and metabolic disease.

“This is an important step for the scientific community as it increases our potential small molecule product offerings at a time when stem cell research gathers momentum and size around the world,” said Stemgent CEO Ian Ratcliffe, in a release.

Last year, Stemgent announced a collaboration with stem cell technology startup Fate Therapeutics Inc. to form a separate entity, called Catalyst, to offer biotechs exclusive access to its induced pluripotent stem cell technology in exchange for an annual fee.

Induced pluripotent stem cells are made by reprogramming adult cells, such as adult skin cells, to an embryonic-like state. The cells are considered of great importance to researchers because they can transform into any of the body’s cell types, giving researchers a tool for use in modeling human disease, discovering and testing drug candidates and developing personalized therapies.

— Heather Chambers

-Advertisement-

Featured Articles

Oberon Eyes Europe for Renewable DME

Leaders of Influence in Law 2024

-Advertisement-
-Advertisement-

Related Articles

-Advertisement-
-Advertisement-
-Advertisement-